Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Medexus Pharmaceuticals's operating assets for the quarter that ended in Mar. 2026 was $140.76 Mil. Medexus Pharmaceuticals's operating liabilities for the quarter that ended in Mar. 2026 was $76.03 Mil. Medexus Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 was $154.98 Mil. Therefore, Medexus Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.42.
Medexus Pharmaceuticals Scaled Net Operating Assets Related Terms
Medexus Pharmaceuticals Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Medexus Pharmaceuticals's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medexus Pharmaceuticals Scaled Net Operating Assets Chart
MEDXF vs ZTS, UTHR: Scaled Net Operating Assets Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medexus Pharmaceuticals Scaled Net Operating Assets vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Medexus Pharmaceuticals's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.42 mean?
Medexus Pharmaceuticals (MEDXF) has a Scaled Net Operating Assets of 0.42 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Medexus Pharmaceuticals and its competitors.
Is Medexus Pharmaceuticals' Scaled Net Operating Assets too high?
Medexus Pharmaceuticals' current Scaled Net Operating Assets is 0.42. Overall, Medexus Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' Scaled Net Operating Assets compare to ZTS and UTHR?
Medexus Pharmaceuticals' Scaled Net Operating Assets of 0.42 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Medexus Pharmaceuticals and its competitors. Medexus Pharmaceuticals's current Scaled Net Operating Assets is 0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (MEDXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.32, compared to a current price of $3.62 — trading 174.2% above its estimated fair value. The current Scaled Net Operating Assets is 0.42. Medexus Pharmaceuticals' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Medexus Pharmaceuticals (MEDXF), the current Scaled Net Operating Assets is 0.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medexus Pharmaceuticals (MEDXF) Overvalued in 2026?
Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued.
The current stock price of $3.62 is trading 174.2% above its estimated GF Value™ of $1.32.
GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for MEDXF:
Scaled Net Operating Assets: 0.42
GF Value™: $1.32 vs. price of $3.62 (174.2% above fair value)
No single metric tells the full story. See the MEDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
60GF Score
Get the complete analysis for MEDXF
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDXF has been successfully added to your 
